These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35176181)

  • 1. The Development of Chiral Nanoparticles to Target NK Cells and CD8
    Wang W; Zhao J; Hao C; Hu S; Chen C; Cao Y; Xu Z; Guo J; Xu L; Sun M; Xu C; Kuang H
    Adv Mater; 2022 Apr; 34(16):e2109354. PubMed ID: 35176181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymer nanoparticles for enhanced immune response: combined delivery of tumor antigen and small interference RNA for immunosuppressive gene to dendritic cells.
    Heo MB; Cho MY; Lim YT
    Acta Biomater; 2014 May; 10(5):2169-76. PubMed ID: 24394635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyanhydride Nanoparticles Induce Low Inflammatory Dendritic Cell Activation Resulting in CD8
    Darling R; Senapati S; Christiansen J; Liu L; Ramer-Tait AE; Narasimhan B; Wannemuehler M
    Int J Nanomedicine; 2020; 15():6579-6592. PubMed ID: 32982219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells.
    Heo MB; Lim YT
    Biomaterials; 2014 Jan; 35(1):590-600. PubMed ID: 24125775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted antigen delivery to dendritic cell via functionalized alginate nanoparticles for cancer immunotherapy.
    Zhang C; Shi G; Zhang J; Song H; Niu J; Shi S; Huang P; Wang Y; Wang W; Li C; Kong D
    J Control Release; 2017 Jun; 256():170-181. PubMed ID: 28414151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outer membrane vesicles engineered to express membrane-bound antigen program dendritic cells for cross-presentation to CD8
    Schetters STT; Jong WSP; Horrevorts SK; Kruijssen LJW; Engels S; Stolk D; Daleke-Schermerhorn MH; Garcia-Vallejo J; Houben D; Unger WWJ; den Haan JMM; Luirink J; van Kooyk Y
    Acta Biomater; 2019 Jun; 91():248-257. PubMed ID: 31003032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy.
    Han HD; Byeon Y; Kang TH; Jung ID; Lee JW; Shin BC; Lee YJ; Sood AK; Park YM
    Int J Nanomedicine; 2016; 11():5729-5742. PubMed ID: 27843314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymer nanoparticles for cross-presentation of exogenous antigens and enhanced cytotoxic T-lymphocyte immune response.
    Song C; Noh YW; Lim YT
    Int J Nanomedicine; 2016; 11():3753-64. PubMed ID: 27540289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
    Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
    Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient Uptake of Recombinant Lipidated Survivin by Antigen-Presenting Cells Initiates Antigen Cross-Presentation and Antitumor Immunity.
    Chiang CY; Chen YJ; Wu CC; Liu SJ; Leng CH; Chen HW
    Front Immunol; 2018; 9():822. PubMed ID: 29755461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responsiveness in a mouse model of combined adoptive immunotherapy with NK and dendritic cells.
    Cui F; Ji J; Lv H; Qu D; Yu C; Yang Y; Xu Y
    J Cancer Res Ther; 2013 Nov; 9 Suppl():S162-8. PubMed ID: 24516054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Light Responsive Nanoparticle-Based Delivery System Using Pheophorbide A Graft Polyethylenimine for Dendritic Cell-Based Cancer Immunotherapy.
    Zhang C; Zhang J; Shi G; Song H; Shi S; Zhang X; Huang P; Wang Z; Wang W; Wang C; Kong D; Li C
    Mol Pharm; 2017 May; 14(5):1760-1770. PubMed ID: 28296410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
    Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
    Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8
    Yu Z; Liu W; He Y; Sun M; Yu J; Jiao X; Han Q; Tang H; Zhang B; Xian Y; Qi J; Gong J; Xin W; Shi G; Shan F; Zhang R; Li J; Wei M
    J Hematol Oncol; 2021 Apr; 14(1):71. PubMed ID: 33910591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells.
    Deauvieau F; Ollion V; Doffin AC; Achard C; Fonteneau JF; Verronese E; Durand I; Ghittoni R; Marvel J; Dezutter-Dambuyant C; Walzer T; Vie H; Perrot I; Goutagny N; Caux C; Valladeau-Guilemond J
    Int J Cancer; 2015 Mar; 136(5):1085-94. PubMed ID: 25046660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid (PLGA) nanoparticle encapsulated tumor antigens.
    Iranpour S; Nejati V; Delirezh N; Biparva P; Shirian S
    J Exp Clin Cancer Res; 2016 Oct; 35(1):168. PubMed ID: 27782834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NK cells mediate clearance of CD8
    Nicolai CJ; Wolf N; Chang IC; Kirn G; Marcus A; Ndubaku CO; McWhirter SM; Raulet DH
    Sci Immunol; 2020 Mar; 5(45):. PubMed ID: 32198222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modification of anti-tumor immunity by tolerogenic dendritic cells.
    Chen L; Hasni MS; Jondal M; Yakimchuk K
    Autoimmunity; 2017 Sep; 50(6):370-376. PubMed ID: 28675711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.